Goldan Keith A.

CFO Keith Goldan buys 3,000 shares of SNDX; cluster pattern with 3 other insiders buying within 14 days as stock down 62.5% from 52-week high

Keith Goldan, CFO of Syndax Pharmaceuticals, purchased 3,000 shares at an unspecified price on 2025-05-19, bringing his holdings to 93,746 shares. This transaction occurs in a cluster context: 3 other insiders also bought within the past 14 days, suggesting coordinated or near-simultaneous accumulation. The stock is currently trading at $9.30, down 62.5% from its 52-week high of $24.81, and down 19.4% over the past 30 days. Against this backdrop of sustained decline, the company reported $20.0M in quarterly revenue against a net loss of $84.8M, highlighting operational unprofitability. Goldan's own prior buy at this ticker on 2024-06-14 generated a 90-day return of -10.2%, showing that his previous accumulation in SNDX did not precede a recovery; the current multi-insider buy pattern occurs as the stock remains materially impaired from its peak.

CFO Keith A. Goldan buys 1,250 shares of SNDX at $20.03 amid negative fundamentals and recent price weakness.

Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals, purchased 1,250 shares at $20.03 on 2024-06-14, adding to a holding of 52.6K shares post-transaction. The purchase occurred as the stock trades at $19.88, down 19.1% from its 52-week high and 2.0% below its 30-day average. The company reported $12.4M in latest-quarter revenue but posted a $-72.4M net loss, with the full fiscal year also unprofitable. The modest purchase size relative to holdings (2.4% increase) and the stock's recent downward trajectory merit investor attention to the company's fundamental trajectory and whether this represents meaningful insider conviction or routine activity.